Fuan Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 113 million yuan, a decrease of 47.74%
According to the Zhitong Finance APP, Fuan Pharmaceutical released its semi-annual report for 2025, showing an operating income of 921 million yuan, a year-on-year decrease of 35.76%. The net profit attributable to shareholders of the listed company was 113 million yuan, a year-on-year decrease of 47.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 48.84%. The basic earnings per share were 0.1 yuan
According to the Zhitong Finance APP, Fuan Pharmaceutical (300194.SZ) released its semi-annual report for 2025, reporting an operating income of 921 million yuan, a year-on-year decrease of 35.76%. The net profit attributable to shareholders of the listed company was 113 million yuan, a year-on-year decrease of 47.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 48.84%. The basic earnings per share were 0.1 yuan
